Clinical trials: XEROSTOMIA
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Burning Mouth Syndrome
The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study
Objectives: to evaluate xerostomia and salivary flow in patients with burning mouth syndrome (BMS) treated with amitriptyline before and after the use of antixerostomic topical medication.
- Trial name
- BMS (NCT01754740)
- Testing
- Uréia
- Where
- Brazil
- Volunteers
- 38 people
- Sponsor
- University of Sao Paulo General Hospital
Oral Health Care
Effects of a Salivary Gland Massage Program on Salivary Flow , Xerostomia, Chewing, and Swallowing, and Oral Health Among Community- Dwelling Older Adults
Purpose: This study aims to evaluate the effectiveness of salivary gland massage on saliva flow, xerostomia, chewing and swallowing, and oral health among community-dwelling elderly.
- Trial name
- NCT07251543
- Testing
- Salivary gland massage, General Oral Health Education
- Where
- Taiwan
- Volunteers
- 108 people
- Sponsor
- Chiayi Christian Hospital
Sjogren's Syndrome, Pediatric ALL
Belimumab After Rituximab in Resistant Primary Juvenile SS
The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome.
- Trial name
- BRRPJS (NCT06410833)
- Testing
- Rituximab, Belimumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Sjögren's Syndrome
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
- Trial name
- NCT07118241
- Testing
- Recombinant Human Proteoglycan 4, Vehicle Control
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Lubris Bio Pty Ltd
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
- Trial name
- NCT06544798
- Testing
- AAV2-hAQP1
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- MeiraGTx, LLC
Quality of Life, Adverse Effects
International Validation of the QLQ-OH17 for Oral Health
Assessment of oral and dental problems is seldom routine in clinical oncology, despite the potential negative impact of these problems on nutritional status, social function and quality of life (QoL).
- Conditions
- Quality of Life, Adverse Effects, Late Effects, Cancer
- Trial name
- QLQ-OH17 (NCT01724333)
- Where
- 14 sites in France, Germany and 8 more
- Volunteers
- 585 people
- Sponsor
- Oslo University Hospital
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Xerostomia, Geriatric
Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients
Background: Xerostomia, or dry mouth, is a prevalent condition among older adults and has significant implications for oral and systemic health.
- Trial name
- NCT06984848
- Testing
- Oral7® mouth spray contains Natural Enzymes (Lactoperoxidase, Glucose Oxidase, Lactoferrin, Lysozyme), Calcium, Xylitol, Aloe Vera, Natural peppermint.
- Where
- Malaysia
- Volunteers
- 100 people
- Sponsor
- ZAINAB MAT YUDIN
Autoimmune Diseases, Sjogren's Syndrome
Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome
Primary Sjögren syndrome is one of the most prevalent autoimmune diseases that present with dry eye and dry mouth. But there is no proven effective treatment for Sjögren syndrome patient.
- Conditions
- Autoimmune Diseases, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT01601028
- Testing
- Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Seoul National University Hospital
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Sjogren's Syndrome, Overactive Bladder Syndrome
Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder
Overactive bladder is more prevalent among the Sjogren syndrome's population compare to the general population. Both anti-muscarinic agent and beta-3 agonist are recommended as second line treatment for overactive bladder…
- Trial name
- NCT04909255
- Testing
- mirabegron, oxybutynin, tolterodine, solifenacin
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Sjogren's Disease, Fatigue
Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study
This prospective longitudinal study will be conducted in patients diagnosed with Sjögren's disease who are followed at the rheumatology outpatient clinic of Kahramanmaras Sutcu Imam University Medical Faculty Hospital.
- Trial name
- NCT07544394
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Sjögren's Disease, Interstitial Lung Disease
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease
- Trial name
- NCT07843381
- Testing
- Telitacicept 160mg, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
SLE (Systemic Lupus), Systemic Sclerosis
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD19 or CD19-BCMA CAR-T in patients with active SLE, SSc, AAV…
- Conditions
- SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06548607
- Testing
- CD19 or CD19-BCMA CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Xerostomia
Effect of 0.1% Pilocarpine Mouthwash on Xerostomia
The aim of this study is to evaluate the effect of 0.1% pilocarpine mouthwash on subjective dryness, minor salivary flow rates and unstimulated whole salivary flow rate in xerostomic patients.
- Trial name
- NCT01627626
- Testing
- Pilocarpine, saline
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Jeong-seong Kwon
Systemic Lupus Erthematosus, Sjogren's Syndrome
Omalizumab for Lupus
Background: Systemic Lupus Erythematosus (SLE or lupus) is an autoimmune disease, which means the body's immune system mistakenly attacks healthy tissue resulting in inflammation and tissue damage.
- Trial name
- NCT01716312
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Xerostomia, Hyperthyroidism
Effect of Childhood Radioiodine Therapy on Salivary Function
Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in adult patients. The impact of pediatric I-131 exposure on salivary function is unknown.
- Conditions
- Xerostomia, Hyperthyroidism, Thyroid Cancer
- Trial name
- NCT02375451
- Testing
- Radioiodine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Boston Children's Hospital
Radiation Injuries, Xerostomia
Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation
Therapeutic irradiation to the head and neck for cancer damages salivary glands present in the radiation field. Despite long recognition of radiation-induced salivary hypofunction, and the associated oral morbidities, the…
- Trial name
- NCT00001523
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)